
October 1, 2026

Dear Members of the Fragile X Syndrome Community,

We would like to share an important update regarding the adolescent open-label extension (OLE) portion of Shionogi's clinical development program evaluating zatolmilast for Fragile X syndrome (FXS).

As previously reported, the respective primary endpoints were not met in the EXPERIENCE-301 (adult) or in the EXPERIENCE-204 (adolescent) studies evaluating zatolmilast in FXS in the U.S. In EXPERIENCE-301 (adult study), positive effects were observed in FXS-Numerical Rating Scale (NRS) language/communication and daily function.

Since announcing those results, we have continued to analyze the data, including additional analyses on the potential impact of zatolmilast in adolescents. Following a comprehensive review and extensive analysis, we have concluded that the efficacy measures utilized in the study did not detect a positive treatment signal in the adolescent population. Therefore, we are discontinuing the adolescent open-label extension (OLE) study, EXPERIENCE-302, for adolescents (ages 17 years and under) only. There have been no new safety findings reported. This information has been shared in advance with study investigators and advocacy group leaders.

The study will remain open for adult participants who wish to continue.

Next Steps

- Study sites will work with participating families and caregivers to support study completion and to help address any questions regarding treatment discontinuation, study procedures, or next steps. Additional details will be provided directly by study investigators and site personnel.
- Individuals who participated in the adolescent study and who are 18 years of age or older by October 31, 2026, may stay in the OLE study without any changes or interruptions.
- Families seeking further information may contact Medinfo@Shionogi.com / (800) 849-9707 or reach out to our advocacy partners at **FRAXA Research Foundation** and the **National Fragile X Foundation (NFXF)** for additional support and resources.

While this news may be disappointing, we remain committed to sharing information openly and transparently with the Fragile X community. We will continue to analyze data from adult participants enrolled in EXPERIENCE-302 and continue our ongoing discussions with the U.S. Food and Drug Administration regarding the totality of the data generated from the zatolmilast development program.

We understand how much hope and effort have been invested in this research. We are grateful for the partnership of the Fragile X syndrome community and will continue to provide updates as they become available.

With deep respect and appreciation,

Juan Carlos Gomez, MD

Chief Medical Officer

Shionogi & Co., Ltd.